Biogen Gets Europe OK for Vumerity Multiple Sclerosis Drug

By Colin Kellaher

Biogen Inc. on Tuesday said the European Commission approved its Vumerity next-generation oral treatment for adults with relapsing-remitting multiple sclerosis.

The Cambridge, Mass., biopharmaceutical company said the approval offers a new treatment option with the established efficacy and safety of its blockbuster MS drug Tecfidera, with low gastrointestinal discontinuation rates.

Biogen previously said Vumerity has been shown to be easier on the gastrointestinal tract than Tecfidera, which is approved in 69 countries and remains the most prescribed oral medication for relapsing MS in the world.

The U.S. Food and Drug Administration approved Vumerity in October 2019, and the drug has since has become the top prescribed oral MS therapy in the U.S. Vumerity also is approved in the U.K. and Switzerland.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

11-16-21 0958ET